Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6780114 | 0.97 | KDM4E (0.48) | KDM4EKMT2ANEK2PKMDPP9 | |
| SCHEMBL29604700 | 0.85 | — | — | |
| SCHEMBL1793505 | 0.80 | — | — | |
| SCHEMBL1282200 | 0.76 | KDM4E (0.37) | KDM4EKMT2ADRD2OPRM1 | |
| SCHEMBL542223 | 0.75 | — | — | |
| SCHEMBL3209516 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL5750787 | 0.74 | KDM4E (0.35) | KDM4EKMT2ADRD2OPRM1 | |
| SCHEMBL7286601 | 0.74 | KDM4E (0.40) | KDM4EKMT2ADRD2OPRM1 | |
| SCHEMBL879719 | 0.74 | KDM4E (0.50) | KDM4EKMT2ANEK2PKMDPP9 | |
| SCHEMBL11610210 | 0.72 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211116-B1 | NOVEL HETEROCYCLIC ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2024-08-07 | — | — | EP | claimed |
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024155864-A1 | SPRK1 INHIBITORS AND METHODS OF USE | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | disclosed |
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116891488-A | Condensed-cyclic compound, pharmaceutical composition containing condensed-cyclic compound and application of condensed-cyclic compound | 成都海博为药业有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-4248877-A | ANTIDEPRESSANTS, ANALGESICS, ANTIMIGRAINE AGENTS | SANDOZ LTD. (CH) | 1981-02-03 | — | — | US | disclosed |
| US-4178377-A | USE TO TREAT PAIN AND MIGRAINE | SANDOZ LTD. (CH) | 1979-12-11 | — | — | US | disclosed |
| US-4110334-A | LIGHT STABILIZERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | KDM4E 2238/4885KMT2A 3716/4885NEK2 3059/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | KDM4E 588/4885KMT2A 72/4885NEK2 1021/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | KDM4E 2711/4885KMT2A 4120/4885NEK2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.